Shares of Zoetis Inc. (NYSE:ZTS – Get Rating) have received a consensus rating of “Moderate Buy” from the eight analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $215.17.
Several equities research analysts have recently commented on the company. The Goldman Sachs Group cut their price target on Zoetis from $207.00 to $180.00 and set a “buy” rating for the company in a research note on Friday, November 4th. StockNews.com started coverage on Zoetis in a research note on Wednesday, October 12th. They set a “buy” rating for the company. William Blair reiterated an “outperform” rating on shares of Zoetis in a research report on Thursday, November 3rd. JPMorgan Chase & Co. cut their price objective on Zoetis from $250.00 to $225.00 and set an “overweight” rating for the company in a research report on Monday, October 17th. Finally, Morgan Stanley cut their price objective on Zoetis from $264.00 to $248.00 and set an “overweight” rating for the company in a research report on Tuesday, November 15th.
Zoetis Price Performance
Shares of NYSE ZTS opened at $145.76 on Monday. The company has a current ratio of 2.27, a quick ratio of 1.48 and a debt-to-equity ratio of 1.12. Zoetis has a twelve month low of $124.15 and a twelve month high of $249.27. The stock has a 50 day moving average of $147.93 and a two-hundred day moving average of $158.81. The stock has a market cap of $67.93 billion, a P/E ratio of 33.28, a P/E/G ratio of 2.76 and a beta of 0.72.
Zoetis (NYSE:ZTS – Get Rating) last issued its quarterly earnings data on Thursday, November 3rd. The company reported $1.21 earnings per share for the quarter, missing analysts’ consensus estimates of $1.24 by ($0.03). Zoetis had a net margin of 25.82% and a return on equity of 48.41%. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.08 billion. During the same quarter in the prior year, the firm posted $1.25 EPS. Zoetis’s quarterly revenue was up .6% compared to the same quarter last year. On average, research analysts forecast that Zoetis will post 4.87 earnings per share for the current year.
Zoetis Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 1st. Shareholders of record on Friday, January 20th will be issued a $0.375 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.33. The ex-dividend date of this dividend is Thursday, January 19th. This represents a $1.50 annualized dividend and a yield of 1.03%. Zoetis’s dividend payout ratio is 29.68%.
Institutional Trading of Zoetis
Large investors have recently bought and sold shares of the company. American National Bank boosted its stake in shares of Zoetis by 469.2% during the second quarter. American National Bank now owns 148 shares of the company’s stock valued at $25,000 after acquiring an additional 122 shares during the last quarter. Psagot Value Holdings Ltd. Israel acquired a new stake in shares of Zoetis during the third quarter valued at $25,000. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its stake in shares of Zoetis by 430.8% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after acquiring an additional 112 shares during the last quarter. Worth Asset Management LLC acquired a new stake in shares of Zoetis during the first quarter valued at $26,000. Finally, McClarren Financial Advisors Inc. acquired a new stake in shares of Zoetis during the third quarter valued at $31,000. Institutional investors and hedge funds own 90.23% of the company’s stock.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zoetis, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Zoetis wasn’t on the list.
While Zoetis currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: news.google.com
